Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Shares Shorted: Short Interest Up 146.8% in September

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) saw a large increase in short interest in September. As of September 30th, there was short interest totaling 130,722 shares, an increase of 146.8% from the September 15th total of 52,967 shares. Based on an average trading volume of 3,343,756 shares, the short-interest ratio is presently 0.0 days. Approximately 5.8% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Wall Street Zen upgraded shares of Lakewood-Amedex Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, September 6th. Weiss Ratings upgraded Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Friday, October 2nd. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Lakewood-Amedex Biotherapeutics Trading Down 9.0%

NASDAQ:LABT traded down $0.06 during trading hours on Wednesday, hitting $0.63. The company had a trading volume of 133,878 shares, compared to its average volume of 1,468,091. The business’s 50-day moving average price is $1.83. The firm has a market capitalization of $1.50 million and a P/E ratio of -0.13. Lakewood-Amedex Biotherapeutics has a 1 year low of $0.62 and a 1 year high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last issued its earnings results on Friday, August 14th. The company reported ($2.75) earnings per share (EPS) for the quarter. On average, equities analysts expect that Lakewood-Amedex Biotherapeutics will post 4.96 earnings per share for the current year.

Lakewood-Amedex Biotherapeutics Company Profile

Lakewood-Amedex Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing anti-infective therapies for bacterial infections. The company’s research is centered on novel antimicrobial compounds intended to address infections caused by drug-resistant bacteria and other pathogens.

Its leading product candidate is Nu-3, a bisphosphocin-based anti-infective therapy being developed for potential use against bacterial infections, including those associated with resistant organisms such as methicillin-resistant Staphylococcus aureus (MRSA).